Philip Morris Is Paying for ZYN Share With a 25% Price Cut

Q3 beat, but Q4 U.S. profit goes to zero as PM resets the nicotine-pouch value proposition.

PM · Earnings Call · 2026-10-21

The beat that guided down

Philip Morris delivered a genuinely strong third quarter. Organic net revenue rose 7.1%, “Q3 adjusted OI exceeded $5 billion for the first time, while our adjusted OI margin reached close to 45%” — Massimo Andolina, Executive (likely CEO or CFO) · 2026-10-21, and adjusted diluted EPS hit a record $2.36. Yet full-year guidance moved to the middle or lower half of the range. The reason is not demand. Management pinned roughly a point of EPS growth on cost pressure from Middle East energy inflation and disruptions in Ukraine, then argued that without those items the year would be mid-to-upper. “If it were not for those inflationary pressures... we would actually be in the mid to upper end of the range.” — Massimo Andolina, Executive (likely CEO or CFO) · 2026-10-21 That is a familiar “transitory cost” defense, but it lands alongside a much more deliberate decision in the U.S.

ZYN’s 20-pouch reset

The U.S. nicotine-pouch business is the hinge. Q3 U.S. net revenue rose almost 23% and gross profit 24%, but adjusted operating company income grew only 1.5% as PM poured money into the brand. Then came the real change: the flagship ZYN portfolio is moving from 15 to 20 pouches per can at the price of the 15-count.

First and foremost, the fact that we are moving our flagship portfolio to an optimized premium price positioning, which de facto means a better value proposition for the consumers, and in practical terms, it means a 25% price reduction on a per pouch basis. We are migrating our entire flagship portfolio from 15 to 20 count at the price of the 15 counts.
Massimo Andolina, Executive (likely CEO or CFO) · 2026-10-21

That is not a promotion. It is a structural value reset, and it will cut revenue per pouch by roughly 25%.Management is explicit that Q4 will be ugly in the U.S.: “Q4 will be a unique quarter of investment. We expect an abnormally low level of U.S. profitability in the fourth quarter with adjusted OCI around zero or slightly negative.” — Massimo Andolina, Executive (likely CEO or CFO) · 2026-10-21 U.S. SG&A was about $370 million in Q3, with another roughly 10% sequential step-up expected in Q4; Q3 is now the proxy for next year’s run rate. The bet is that broader distribution, new variants, and higher nicotine levels — ZYN Ultra at 9 mg and 11 mg — plus an expanded dry portfolio can lift Category share enough to absorb the price reset. Early evidence is not nothing: ZYN’s estimated category offtake share rose 1.4 points from June to September.But contrast this with the prior playbook. In Q2 2026 management said it would pull “every lever we can pull to accelerate the growth of ZYN and leveraging this new situation” — Emmanuel Babeau, Group CFO · 2026-07-22; in Q3 2025 the U.S. issue was framed as a “€100,000,000… one off” — Emmanuel Babeau, Chief Financial Officer · 2025-10-21 promotion and a return to normal promotional activity. The current move is bigger and more permanent: a premium brand is buying volume with price. That is why commercial investment is now the keyword that matters more than any single promo.

IQOS and the combustible cash engine

IQOS remains the profit engine. Adjusted in-market sales grew 7.1% in Q3 and 7.7% year to date; excluding Japan and Poland, growth was around 10%. HTU shipments were 41.5 billion units, and Q4 is guided to 39.5 billion–40.5 billion as Japan works through the two-step excise increase. The shipment-versus-IMS gap is a familiar pantry loading story, not a demand break. International smoke-free gross margin is still around 70%, and the geographic base is widening — Germany, Spain, Italy, Greece, Indonesia, Mexico, Taiwan, and travel retail all contributed.Combustibles are doing the quiet lifting. Third-quarter pricing was +8.9%, year-to-date +9.1%, and international category share rose 0.4 points to 25.9%, with Marlboro at a record 11.4%. That resilience creates an unfavorable geographic mix because the strongest volume markets are places where smoke-free is banned or limited, but it also throws off the cash to fund ZYN’s reset. Germany’s higher excise path is a new regulatory headwind, though management argues the heated-tobacco tax differential remains and Marlboro’s brand strength gives PM room to compete.

What the tape and the accounts say

The stock is not priced for a broken story. PM is up 8.6% over 90 days, closed near a high of $205.58 on October 14, and sits only 3.9% below that peak. The market appears willing to look through a weak Q4 U.S. profit print. The last filed quarter showed $11.2 billion of revenue, a 68.4% gross margin, and a 40.5% operating margin. But the balance sheet still carries -$36.3 billion of effective net cash, and the shares trade at 24.7x price-to-net-income, down sharply from last year’s peak multiple.The dividend was raised for the 19th consecutive year to $6.40, up almost 9%, and management still expects record operating cash flow of about $13.5 billion. So the company can afford the ZYN reset. The question is whether it is buying durable share or defending a premium position that competitors have already eroded. Management’s own consumer logic — that users consume more when they have more pouches in the pack — is plausible, but it is a hope, not yet a proven P&L offset. For now, PM has delivered the quarter and guided down the year, while making its biggest U.S. brand cheaper. That is the tension investors have to underwrite.